Description

This program explored the role of evolocumab in preventing first major cardiovascular events in high-risk patients without prior MI or stroke, and gain practical insights for your clinical practice.

Learning  Objectives

• Identification of high-risk patients without prior CV events
• Discuss the spectrum of primary vs. secondary CV prevention
• Learn about the role of evolocumab in patients with subclinical atherosclerosis or high-risk diabetes

Faculty

Milan Gupta, MD, FRCPC, FCCS, CPC(HC)

Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA, FACC

This program was developed by CCRN and has received unrestricted educational grant funding.

Program slides:

A copy of the program slides is available for CCRN members with a resource library subscription. View pricing and download options on the Resources tab.